{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:18:12Z","timestamp":1787699892117,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16362-y","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:02:56Z","timestamp":1781661776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative assessment of asparaginase activity, population pharmacokinetics, and safety of biosimilar native Escherichia coli and pegylated asparaginase in children with newly diagnosed acute lymphoblastic leukemia: a pharmacometrics-based randomized clinical trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3825-3711","authenticated-orcid":false,"given":"Sujitha","family":"Sethuramalingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Kumar","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9318-1167","authenticated-orcid":false,"given":"Praveen","family":"Kumar-M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-1773","authenticated-orcid":false,"given":"Debasish","family":"Hota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janhavi","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0663-0922","authenticated-orcid":false,"given":"Anand","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"2","key":"16362_CR1","first-page":"83","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83\u2013103.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"16362_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","volume":"97","author":"LB Silverman","year":"2001","unstructured":"Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91\u201301. Blood. 2001;97(5):1211\u20138.","journal-title":"Blood"},{"issue":"3","key":"16362_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.leu.2401310","volume":"13","author":"MD Amylon","year":"1999","unstructured":"Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335\u201342.","journal-title":"Leukemia"},{"issue":"28","key":"16362_CR4","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","volume":"23","author":"A Pession","year":"2005","unstructured":"Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(28):7161\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"16362_CR5","first-page":"241","volume":"1","author":"VI Avramis","year":"2006","unstructured":"Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006;1(3):241\u201354.","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"16362_CR6","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","volume":"32A","author":"J Boos","year":"1996","unstructured":"Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996;32A(9):1544\u201350.","journal-title":"Eur J Cancer"},{"issue":"4","key":"16362_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x","volume":"96","author":"E Ahlke","year":"1997","unstructured":"Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 1997;96(4):675\u201381.","journal-title":"Br J Haematol"},{"issue":"2","key":"16362_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/A:1008368916800","volume":"11","author":"C Rizzari","year":"2000","unstructured":"Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol. 2000;11(2):189\u201393.","journal-title":"Ann Oncol"},{"issue":"3","key":"16362_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2015.137380","volume":"101","author":"IM van der Sluis","year":"2016","unstructured":"van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279\u201385.","journal-title":"Haematologica"},{"key":"16362_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","volume":"11","author":"C Bender","year":"2021","unstructured":"Bender C, Maese L, Carter-Febres M, Verma A. Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. Blood Lymphat Cancer. 2021;11:25\u201340.","journal-title":"Blood Lymphat Cancer"},{"issue":"2","key":"16362_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/08880018.2011.627978","volume":"29","author":"S Borghorst","year":"2012","unstructured":"Borghorst S, Pieters R, Kuehnel HJ, Boos J, Hempel G. Population pharmacokinetics of native Escherichia coli asparaginase. Pediatr Hematol Oncol. 2012;29(2):154\u201365.","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"16362_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s13318-017-0410-5","volume":"42","author":"G Wurthwein","year":"2017","unstructured":"Wurthwein G, Lanvers-Kaminsky C, Hempel G, et al. Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar((R)) in Children with Acute Lymphoblastic Leukemia. Eur J Drug Metab Pharmacokinet. 2017;42(6):955\u201363.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"16362_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.htct.2019.01.013","volume":"42","author":"CV Medawar","year":"2020","unstructured":"Medawar CV, Mosegui GBG, Vianna CMM, Costa T. PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review. Hematol Transfus Cell Ther. 2020;42(1):54\u201361.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"1","key":"16362_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13063-022-06033-1","volume":"23","author":"N Das","year":"2022","unstructured":"Das N, Banavali S, Bakhshi S, et al. Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials. 2022;23(1):102.","journal-title":"Trials"},{"issue":"13","key":"16362_CR15","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1182\/blood-2008-04-149443","volume":"112","author":"R Pieters","year":"2008","unstructured":"Pieters R, Appel I, Kuehnel HJ, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008;112(13):4832\u20138.","journal-title":"Blood"},{"issue":"1","key":"16362_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0003-2697(02)00232-4","volume":"309","author":"C Lanvers","year":"2002","unstructured":"Lanvers C, Vieira Pinheiro JP, Hempel G, Wuerthwein G, Boos J. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem. 2002;309(1):117\u201326.","journal-title":"Anal Biochem"},{"issue":"9","key":"16362_CR17","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","volume":"11","author":"BL Asselin","year":"1993","unstructured":"Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11(9):1780\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"16362_CR18","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood. 2002;99(6):1986\u201394.","journal-title":"Blood"},{"key":"16362_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1200\/GO.20.00113","volume":"6","author":"M Nookala Krishnamurthy","year":"2020","unstructured":"Nookala Krishnamurthy M, Narula G, Gandhi K, et al. Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia. JCO Glob Oncol. 2020;6:1009\u201316.","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"16362_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2141.2009.07923.x","volume":"148","author":"G Hempel","year":"2010","unstructured":"Hempel G, Muller HJ, Lanvers-Kaminsky C, Wurthwein G, Hoppe A, Boos J. A population pharmacokinetic model for pegylated-asparaginase in children. Br J Haematol. 2010;148(1):119\u201325.","journal-title":"Br J Haematol"},{"key":"16362_CR21","doi-asserted-by":"publisher","first-page":"e29046","DOI":"10.1002\/pbc.29046","volume":"68","author":"J Sidhu","year":"2021","unstructured":"Sidhu J, Gogoi MP, Agarwal P, et al. Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2021;68:e29046.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"16362_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","volume":"26","author":"EH Panosyan","year":"2004","unstructured":"Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children\u2019s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217\u201326.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"16362_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.21037\/tp-20-178","volume":"10","author":"ZJ Dai","year":"2021","unstructured":"Dai ZJ, Huang YQ, Lu Y. Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis. Transl Pediatr. 2021;10(2):244\u201355.","journal-title":"Transl Pediatr"},{"issue":"5-6","key":"16362_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/08880018.2018.1538277","volume":"35","author":"C Vyas","year":"2018","unstructured":"Vyas C, Jain S, Kapoor G, Mehta A, Takkar Chugh P. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity. Pediatr Hematol Oncol. 2018;35(5\u20136):331\u201340.","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"16362_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/bjh.12733","volume":"165","author":"RA Raja","year":"2014","unstructured":"Raja RA, Schmiegelow K, Albertsen BK, et al. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. Br J Haematol. 2014;165(1):126\u201333.","journal-title":"Br J Haematol"},{"issue":"16","key":"16362_CR26","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","volume":"16","author":"AE Place","year":"2015","unstructured":"Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05\u2013001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677\u201390.","journal-title":"Lancet Oncol"},{"issue":"6","key":"16362_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1177\/10781552231190827","volume":"30","author":"BK Panda","year":"2024","unstructured":"Panda BK, Gaikwad M, Bafna V, Vaidya N, Aundhe V, Mhatre A. Adverse events associated with Pegaspargase biosimilar in pediatric patients with acute lymphoblastic leukemia: a prospective single-center study. J Oncol Pharm Pract. 2024;30(6):958\u201363.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"16362_CR28","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4103\/ijmpo.ijmpo_110_17","volume":"38","author":"D Jayaraman","year":"2017","unstructured":"Jayaraman D, Uppuluri R, Swaminathan VV, Sivasankaran M, Patel S, Raj R. Affordable and safe health care for all children: lessons learned from the use of Peg-asparaginase in a developing country. Indian J Med Paediatr Oncol. 2017;38(3):398\u2013400.","journal-title":"Indian J Med Paediatr Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16362-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:58:05Z","timestamp":1787698685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16362-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16362"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16362-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial commenced after the approval of the Institutional Ethics Committee of AIIMS Bhubaneswar (IEC Reference Number: EC\/AIIMS BBSR\/PG Thesis\/2018\u201319\/31, Date of approval: December 20, 2018). Informed consent was obtained from every participant (parent or guardian for minors) before they were enrolled in the research. The research was done with ethical standards in accordance with the \u2018Declaration of Helsinki\u2019. \u2018National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017)\u2019 by the Indian Council of Medical Research was implemented while conducting research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The support and logistics of the study were provided by Gennova Biopharmaceuticals Ltd. Dr.Praveen Kumar Agarwal, Ms. Janhavi Gopal, and Ms. Aishwarya Kulkarni are employed by Gennova Biopharmaceuticals Ltd.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1023"}}